Secnidazole - Laboratoires IPRAD

Drug Profile

Secnidazole - Laboratoires IPRAD

Alternative Names: Secnol

Latest Information Update: 04 Sep 2015

Price : $50

At a glance

  • Originator Laboratoires IPRAD
  • Class Antibacterials; Antiprotozoals; Nitroimidazoles; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Amoebiasis; Bacterial vaginosis; Giardiasis; Urethritis; Vaginitis

Most Recent Events

  • 20 Jul 2015 Launched for Amoebiasis in France (PO) (before July 2015)
  • 20 Jul 2015 Launched for Vaginitis in France (PO) (before July 2015)
  • 20 Jul 2015 Launched for Urethritis in France (PO) (before July 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top